PDCD1 and esophageal cancer: Five patients with advanced gastrointestinal tumors (2 gastric cancers, 1 esophageal cancer, 1 colorectal cancer, and 1 breast cancer) who previously failed anti–PD-1 monotherapy completed in this study.